Spacecraft Dormancy Autonomy Analysis for a Crewed Martian Mission

Current concepts of operations for human exploration of Mars center on the staged deployment of spacecraft, logistics, and crew. Though most studies focus on the needs for human occupation of the spacecraft and habitats, these resources will spend most of their lifetime unoccupied. As such, it is important to identify the operational state of the unoccupied spacecraft or habitat, as well as to design the systems to enable the appropriate level of autonomy. Key goals for this study include providing a realistic assessment of what "dormancy" entails for human spacecraft, exploring gaps in state-of-the-art for autonomy in human spacecraft design, providing recommendations for investments in autonomous systems technology development, and developing architectural requirements for spacecraft that must be autonomous during dormant operations. The mission that was chosen is based on a crewed mission to Mars. In particular, this study focuses on the time that the spacecraft that carried humans to Mars spends dormant in Martian orbit while the crew carries out a surface mission. Communications constraints are assumed to be severe, with limited bandwidth and limited ability to send commands and receive telemetry. The assumptions made as part of this mission have close parallels with mission scenarios envisioned for dormant cis-lunar habitats that are stepping-stones to Mars missions. As such, the data in this report is expected to be broadly applicable to all dormant deep space human spacecraft

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

New particle formation in the Front Range of the Colorado Rocky Mountains

New particle formation is of interest because of its influence on the properties of aerosol population, and due to the possible contribution of newly formed particles to cloud condensation nuclei. Currently no conclusive evidence exists as to the mechanism or mechanisms of nucleation and subsequent particle growth. However, nucleation rates exhibit a clear dependence on ambient sulphuric acid concentrations and particle growth is often attributed to the condensation of organic vapours. A detailed study of new particle formation in the Front Range of the Colorado Rocky Mountains is presented here. Gas and particle measurement data for 32 days was analyzed to identify event days, possible event days, and non-event days. A detailed analysis of nucleation and growth is provided for four days on which new particle formation was clearly observed. Evidence for the role of sesquiterpenes in new particle formation is presented